Taro Pharmaceutical Industries - TARO Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TARO shares.
View TARO analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year price objectives for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $35.00 to $35.00. On average, they anticipate the company's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price.
View analysts price targets for TARO or view top-rated stocks among Wall Street analysts.

Taro Pharmaceutical Industries' stock was trading at $29.04 on January 1st, 2023. Since then, TARO shares have decreased by 13.9% and is now trading at $25.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 25th 2023.
View our TARO earnings forecast.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Tuesday, January, 24th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.87 by $0.68. The firm earned $139.20 million during the quarter, compared to analysts' expectations of $163.12 million. Taro Pharmaceutical Industries had a net margin of 8.06% and a trailing twelve-month return on equity of 2.68%.

ETFs with the largest weight of Taro Pharmaceutical Industries (NYSE:TARO) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL) and iShares MSCI Israel ETF (EIS).VanEck Israel ETF (ISRA).

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Taro Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.63%), Dimensional Fund Advisors LP (1.52%), Eversept Partners LP (0.60%), Murchinson Ltd. (0.28%), Cowen AND Company LLC (0.19%) and ARK Investment Management LLC (0.18%).

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TARO stock can currently be purchased for approximately $25.00.

Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $939.63 million and generates $569.41 million in revenue each year. The company earns $58.27 million in net income (profit) each year or $1.22 on an earnings per share basis.

The company employs 1,455 workers across the globe.

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.